Onconetix, Inc. Contingent Consideration Classified as Equity, Fair Value Disclosure
Onconetix, Inc. (ONCO) had Contingent Consideration Classified as Equity, Fair Value Disclosure of $254.00 thousand as of 2022-09-30, per its 10-Q filed 2022-11-14.
Discontinued › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure · last filed 2022-11-14
- 2022-09-30: Contingent Consideration Classified as Equity, Fair Value Disclosure $254.00K.
| Period end | Contingent Consideration Classified as Equity, Fair Value Disclosure |
|---|---|
| 2022-09-30 | $254.00K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |